Transforming growth factor beta receptor type I (with Smad-dependent signaling) (TGF-βRI (ALK5), with associated SMAD2/3/4)

The TGF-β1/Smad signaling pathway is a canonical cell signaling cascade where the cytokine transforming growth factor beta 1 (TGF-β1) binds and activates a heteromeric complex of TGF-β type II and type I serine/threonine kinase receptors at the cell surface[1][7][6]. Upon ligand binding, the type II receptor phosphorylates and activates the type I receptor, which in turn phosphorylates receptor-regulated Smad proteins (Smad2 and Smad3)[1][2][7]. These Smads form a complex with the common Smad4 and translocate to the nucleus, regulating the transcription of genes involved in cellular proliferation, differentiation, apoptosis, matrix production, and immune responses[6][7]. Deregulation of this pathway contributes to numerous diseases, including cancer, fibrosis, and immune disorders[7]. Therapeutic interest centers on modulating the pathway at the receptor or Smad level for anti-fibrotic, anti-tumor, or immunomodulatory effects.

Other names

TGF-β/Smad signalingTGF-β pathwayCanonical TGF-β signalingTGFBR-SMAD axis

Inhibition of TGF-β receptor kinase activity (e.g., small molecule inhibitors of type I receptor); Blockade of ligand-receptor interaction by monoclonal antibodies; Interference with Smad phosphorylation and nuclear translocation.